CYP3A4 and malaria: The Co-administration of artemether lumefantrine (AL) with ciprofloxacin as treatment for malaria-typhoid co-infection is common in Nigeria and this increases risk of pharmacokinetic drug-drug interaction since ciprofloxacin is an inhibitor of CYP3A4 that metabolizes AL.